Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 2/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.40 |
| ▸ | CDK2 | P24941 | 6/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.40 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 4/20 | 0.35 |
| ▸ | ITK | Q08881 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9221036 | 0.81 | TSHR (0.41) | IKBKBAADATHDAC9 | |
| SCHEMBL28587591 | 0.80 | HDAC3 (0.41) | HDAC9AURKAITKLCK | |
| SCHEMBL6795570 | 0.77 | CCNA2 (0.59) | IKBKBCCNA2CDK2CCNA1AURKA | |
| SCHEMBL28573732 | 0.77 | ITK (0.36) | CDC25BAURKAITKLCK | |
| SCHEMBL6632616 | 0.74 | XDH (0.43) | IKBKBCCNA2CDK2CCNA1 | |
| SCHEMBL9219795 | 0.73 | PLK4 (0.41) | AADATALDH1A1AURKAHPGDLMNA | |
| SCHEMBL28587710 | 0.72 | HDAC6 (0.36) | IKBKBHDAC9AURKAITK | |
| SCHEMBL6661004 | 0.72 | CCNA2 (0.59) | IKBKBCCNA2CDK2CCNA1AURKA | |
| SCHEMBL28570874 | 0.71 | IKBKB (0.44) | IKBKBHDAC9 | |
| SCHEMBL1160454 | 0.71 | NPC1 (0.49) | CCNA2CDK2CCNA1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | IKBKB 634/4885CCNA2 270/4885CDK2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.